Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.
about
Matrix metalloproteinases in kidney homeostasis and diseasesMMP-9- and NMDA receptor-mediated mechanism of diabetic renovascular remodeling and kidney dysfunction: hydrogen sulfide is a key modulator.Epigenetic regulation of aortic remodeling in hyperhomocysteinemia.Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?Ouabain stimulates Na-K-ATPase through a sodium/hydrogen exchanger-1 (NHE-1)-dependent mechanism in human kidney proximal tubule cellsFunctional consequences of the collagen/elastin switch in vascular remodeling in hyperhomocysteinemic wild-type, eNOS-/-, and iNOS-/- miceCystathionine β-synthase and cystathionine γ-lyase double gene transfer ameliorate homocysteine-mediated mesangial inflammation through hydrogen sulfide generationFolic acid mitigates angiotensin-II-induced blood pressure and renal remodeling.Remodeling in vein expresses arterial phenotype in hyperhomocysteinemia.Increased endogenous H2S generation by CBS, CSE, and 3MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia.DNA hypermethylation in hyperhomocysteinemia contributes to abnormal extracellular matrix metabolism in the kidneyVascular Matrix Metalloproteinase Inhibition, a New Mechanism for How Peroxisome Proliferator-Activated Receptor-γ Protects Target Organ Damage.Hydrogen sulfide deficiency and diabetic renal remodeling: role of matrix metalloproteinase-9.Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure.Protective Effects of Hydrogen Sulfide in the Ageing Kidney.Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension.Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiologyHomocysteine inhibits adipogenesis in 3T3-L1 preadipocytes.
P2860
Q27004621-9B46AC99-8273-4E44-88FB-1EC2EC6BDA7AQ30384879-85A952C3-B570-4CA5-BCBA-8678AD40D8B6Q33913216-D4AD2E13-1DCE-4457-B9D7-C5D0F1BA8FBBQ33953983-CBB2C403-928C-48FF-AC12-8C82B230EC42Q33995175-2D0FBFCA-762E-4A35-8C30-EB24E9FEAD20Q34180783-2292BB47-A2CF-4CA7-A532-3B5A0877B004Q34501679-5AD5A43F-FAE7-4B28-9875-9F41A20A5720Q35080666-ECFF7788-1E98-420B-AE5A-03F9BD44CC7DQ35591408-A78FD411-A4C7-4B87-B7C3-3E7EF9F47EBFQ36114692-E6CA3E4C-0578-4396-9E74-D42BF2E77DDFQ36171329-4BF7E99E-5A42-44FF-AA1F-CA89F9E36CF6Q36373024-FDBC41B9-16B6-498B-852D-FE8A2750300DQ36923702-E2C5D029-029E-4AEF-A91F-C0CF9125AA50Q37298478-BBB337DA-17EC-4AF9-8EAF-138E44530A99Q37413619-468DFB6D-8289-44CC-88C8-0BB652ED0D90Q38948319-CD57965A-B132-48D3-A53A-B9298F886F25Q41374334-94C20776-E896-4E74-8BC0-8B00679D8ECCQ42339328-88E424A6-E865-47CA-9FD4-330EA114588F
P2860
Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Ciglitazone, a PPARgamma agoni ...... hrough homocysteine clearance.
@en
type
label
Ciglitazone, a PPARgamma agoni ...... hrough homocysteine clearance.
@en
prefLabel
Ciglitazone, a PPARgamma agoni ...... hrough homocysteine clearance.
@en
P2093
P2860
P1476
Ciglitazone, a PPARgamma agoni ...... hrough homocysteine clearance.
@en
P2093
Munish Kumar
Neetu Tyagi
Soumi Kundu
Suresh C Tyagi
Walter E Rodriguez
P2860
P304
P356
10.1152/AJPENDO.90534.2008
P577
2008-09-09T00:00:00Z